These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

777 related articles for article (PubMed ID: 33810866)

  • 1. Reply to the letter to the editor 'Reply to Solinas et al, venous and arterial thromboembolic events with immune checkpoint inhibitors: A systematic review' by Frere et al.
    Petrelli F; Solinas C
    Thromb Res; 2021 Dec; 208():217-218. PubMed ID: 33810866
    [No Abstract]   [Full Text] [Related]  

  • 2. Letter to the editors-in-chief reply to: Solinas et al. Venous and arterial thromboembolic events with immune check point inhibitors: A systematic review.
    Frere C; Ederhy S; Salem JE
    Thromb Res; 2021 Dec; 208():214-216. PubMed ID: 33678421
    [No Abstract]   [Full Text] [Related]  

  • 3. Reply to Johanna Noel, Olivier Huillard, and Francois Goldwasser's Letter to the Editor re: Keiichiro Mori, Mohammad Abufaraj, Hadi Mostafaei, et al. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.10.006. Clinical Activity of Immune Checkpoint Inhibitors: Is the Host the Answer?
    Mori K; Schmidinger M; Egawa S; Gust KM; Shariat SF
    Eur Urol; 2021 Apr; 79(4):e113-e114. PubMed ID: 33487477
    [No Abstract]   [Full Text] [Related]  

  • 4. Reply to Nirmish Singla and Vitaly Margulis's Letter to the Editor re: Geraldine Pignot, Antoine Thiery-Vuillemin, Jochen Walz, et al. Nephrectomy After Complete Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma: A New Surgical Challenge? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.12.018. The Next Surgical Frontier in Kidney Cancer: Nephrectomy After Immune Checkpoint Inhibition: Nephrectomy After Immunotherapy: The Duration of Treatment Exposure is Probably Decisive.
    Pignot G; Thiery-Vuillemin A; Walz J; Bigot P; Bensalah K; Gravis G; Barthélémy P
    Eur Urol; 2020 Aug; 78(2):e81-e82. PubMed ID: 32389444
    [No Abstract]   [Full Text] [Related]  

  • 5. Authors reply to letter to the editor by Dr Degens et al.
    Bommart S; Pujol JL; Coffy A; Daurès JP; Roch B
    Lung Cancer; 2021 Mar; 153():185. PubMed ID: 33461818
    [No Abstract]   [Full Text] [Related]  

  • 6. Venous and arterial thromboembolic events with immune checkpoint inhibitors: A systematic review.
    Solinas C; Saba L; Sganzerla P; Petrelli F
    Thromb Res; 2020 Dec; 196():444-453. PubMed ID: 33065409
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Mittal A; Arun Raj ST; Gupta A; Shamim SA; Barwad A; Rastogi S
    J Adolesc Young Adult Oncol; 2021 Aug; 10(4):501-502. PubMed ID: 33326306
    [No Abstract]   [Full Text] [Related]  

  • 8. Letter by Sarayani et al Regarding Article, "Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque".
    Sarayani A; Jugl S; Winterstein AG
    Circulation; 2021 Jun; 143(25):e1031-e1032. PubMed ID: 34152796
    [No Abstract]   [Full Text] [Related]  

  • 9. Reply to "Immune checkpoint inhibitor-related dermatologic adverse events".
    Stephan C; Khalil J; Abbas O
    J Am Acad Dermatol; 2021 Jun; 84(6):e297-e298. PubMed ID: 33662463
    [No Abstract]   [Full Text] [Related]  

  • 10. Reply to: Combining TNF blockade with immune checkpoint inhibitors in patients with cancer.
    Chen AY; Wolchok JD; Bass AR
    Nat Rev Rheumatol; 2021 Sep; 17(9):577-578. PubMed ID: 34226728
    [No Abstract]   [Full Text] [Related]  

  • 11. Reply to Letter to the Editor "Readers response to: 'Diagnosis and management of carotid free-floating thrombus: A systematic literature review'".
    Fridman S; Lownie SP; Mandzia J
    Int J Stroke; 2019 Dec; 14(9):NP5. PubMed ID: 31640490
    [No Abstract]   [Full Text] [Related]  

  • 12. Response to letter entitled: Re: Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials.
    Agostinetto E; Ceppi M; Bruzzone M; Lambertini M; de Azambuja E
    Eur J Cancer; 2021 Sep; 155():303-306. PubMed ID: 34366207
    [No Abstract]   [Full Text] [Related]  

  • 13. Reply to Y. Inagaki et al.
    Abu-Sbeih H; Faleck DM; Dougan M; Wang Y
    J Clin Oncol; 2020 May; 38(15):1749-1750. PubMed ID: 32250720
    [No Abstract]   [Full Text] [Related]  

  • 14. Letter to the Editor Regarding "Cutaneous Toxicities in Lung Cancer Patients on Immune Checkpoint Inhibitor Therapy".
    Satoh H; Miyazaki K; Kagohashi K
    Clin Lung Cancer; 2021 Sep; 22(5):e782. PubMed ID: 33781693
    [No Abstract]   [Full Text] [Related]  

  • 15. Correspondence on 'Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation' by Braaten
    Ceccarelli F; Botticelli A; Gelibter AJ; Leccese I; Lucchetti R; Cortesi E; Valesini G; Marchetti P; Conti F
    Ann Rheum Dis; 2022 Jan; 81(1):e13. PubMed ID: 31907163
    [No Abstract]   [Full Text] [Related]  

  • 16. Erratum to: Letter to the editor re: Li et al. (2020), 'The potential role of bacteria in pancreatic cancer: A systematic review'.
    Kountouras J; Papaefthymiou A; Polyzos SA; Zavos C; Doulberis M
    Carcinogenesis; 2020 Oct; 41(10):1460. PubMed ID: 32770238
    [No Abstract]   [Full Text] [Related]  

  • 17. Reply from Lynch et al. to letter from Vedpathak and Shah regarding 'When should physical rehabilitation commence after stroke: a systematic review'.
    Lynch E; Hillier S; Cadilhac D
    Int J Stroke; 2015 Feb; 10(2):E12. PubMed ID: 25598027
    [No Abstract]   [Full Text] [Related]  

  • 18. Risk of venous and arterial thromboembolic events in women with advanced breast cancer treated with CDK 4/6 inhibitors: A systematic review and meta-analysis.
    Bolzacchini E; Pomero F; Fazio M; Civitelli C; Fabro G; Pellegrino D; Giordano M; Squizzato A
    Thromb Res; 2021 Dec; 208():190-197. PubMed ID: 34814055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Predictive Biomarkers of Immune-related Adverse Events Induced by Checkpoint Inhibitors in Malignancies].
    Tang H; Guan M; Sun Z; Bai CM
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2020 Dec; 42(6):825-830. PubMed ID: 33423733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Re: Keiichiro Mori, Mohammad Abufaraj, Hadi Mostafaei, et al. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.10.006: Clinical Activity of Immune Checkpoint Inhibitors: Is the Host the Answer?
    Noel J; Huillard O; Goldwasser F
    Eur Urol; 2021 Apr; 79(4):e112. PubMed ID: 33518379
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 39.